Last reviewed · How we verify

NCT04185753

Chronotropic Incompetence During Exercise Testing in Obese Adolescents

Status unknown Last updated 4 December 2019
What this trial tests

trial testing The prevalence of chronotropic incompetence during maximal cardiopulmonary exercise testing in Obesity, Childhood in 60 participants. Status unknown.

Timeline
29 November 2019
Primary endpoint
15 January 2020
30 January 2020

Quick facts

Lead sponsorHasselt University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment60
Start date29 November 2019
Primary completion15 January 2020
Estimated completion30 January 2020
Sites1 location across Belgium

Drugs / interventions tested

Conditions studied

Sponsor

Hasselt University

Who can join

Adults 11 to 17, any sex, with Obesity, Childhood or Cardiac Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In adolescents with obesity cardiopulmonary exercise testing (CPET) has become an important clinical examination providing valuable information with regard to the integrative exercise responses, including the pulmonary, cardiovascular and muscular systems. During CPET, mechanical constraints in ventilation, an elevated risk for hypoxia and chronotropic incompetence (CI) (defined as the inability of the heart to increase its rate with increased activity), or compromised cardiac function (e.g. lowered heart rate (HR) recovery, chronotropic index and stroke volume) are often observed in obese adults. Moreover, several studies regarding exercise capacity and cardiopulmonary responses to maximal endurance exercise testing have been performed in obese adolescents. Despite these previous investigations in obese adolescents it remains controversial whether cardiopulmonary disturbances can be observed consistently during CPET. However, a number of studies have reported a suboptimal response to exercise, in particular a reduced peak heart rate (HRpeak) and peak cycling power output (Wpeak). Adult obesity modifies cardiac behavior, including resting HR and CI, which has a marked effect on exercise capacity. Therefore, chronotropic variables are the most important factors that affect exercise performance. It has been shown that both peak and resting HR account for over forty percent of variability of exercise capacity. Interestingly, resting HR and HR response to exercise, including a blunted HR increase, low chronotropic index and HR recovery, are important predictors of all-cause mortality and cardiovascular death, at least in adults. These changes in HR during and recovery from CPET are mediated by the balance between sympathetic and vagal activity of the autonomic nervous system. Adverse cardiovascular outcomes associated with the metabolic syndrome may be mediated by autonomic dysfunction, whereby obesity is characterized by sympathetic predominance and a decrease in vagal activity in the basal state, where reduced sympathetic responsiveness has been observed during exercise. Therefore, these multiple exercise risk markers could provide valuable clinical information regarding cardiometabolic health. Nonetheless HR behavior during CPET has not been described in obese adolescents. The goal of this study is to examine the HR behavior of obese adolescents during CPET to clarify whether this population suffer from CI.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Chronotropic incompetence is more frequent in obese adolescents and relates to systemic inflammation and exercise intolerance.
    Franssen WMA, Keytsman C, Marinus N, Verboven K, et al · · 2023 · cited 10× · PMID 33529767 · DOI 10.1016/j.jshs.2021.01.010

Verify or expand the search:

Other recruiting trials for Obesity, Childhood

Currently open trials in the same condition.

Other Hasselt University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04185753.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing